Lana Kandalaft, Chief of Clinical and Translational Research at Swiss Medical Network, shared on LinkedIn:
“We are very pleased to see our review entitled ‘Strategies to develop therapeutic cancer vaccines for pancreatic cancer’ finally out in the lancet journal. It is very timely.”
Title: Strategies to develop therapeutic cancer vaccines for pancreatic cancer
Authors: Matilde M. Coppi, Michele Graciotti, Antonia Digklia, Lana E. Kandalaft
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, with limited benefits from conventional immunotherapies. This review evaluates clinical trials of therapeutic cancer vaccines, highlighting their favourable safety profiles and ability to stimulate antitumour immune responses, although clinical benefits remain limited.
Personalised neoantigen vaccines, particularly mRNA-based approaches, show promising results. Future progress will depend on combining vaccines with other treatments and conducting biomarker-guided clinical trials.
Read the full article.
You may also be interested in: Nelson Dusetti Highlights New Insights Into Pancreatic Cancer Treatment Resistance
